tolbutamide has been researched along with Glioma in 3 studies
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our previous work has shown that tolbutamide increases gap junctional permeability in poorly coupled C6 glioma cells and that this effect is similar and additive to that found with dbcAMP, a well-known activator of gap junctional communication." | 7.73 | Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up-regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation. ( Herrero-González, S; Medina, JM; Paíno, T; Sánchez-Alvarez, R; Tabernero, A, 2006) |
| "Our previous work has shown that tolbutamide increases gap junctional permeability in poorly coupled C6 glioma cells and that this effect is similar and additive to that found with dbcAMP, a well-known activator of gap junctional communication." | 3.73 | Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up-regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation. ( Herrero-González, S; Medina, JM; Paíno, T; Sánchez-Alvarez, R; Tabernero, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sánchez-Alvarez, R | 3 |
| Tabernero, A | 3 |
| Medina, JM | 3 |
| Paíno, T | 1 |
| Herrero-González, S | 1 |
| Sánchez-Abarca, LI | 1 |
| Orfao, A | 1 |
| Giaume, C | 1 |
3 other studies available for tolbutamide and Glioma
| Article | Year |
|---|---|
The increase in gap junctional communication decreases the rate of glucose uptake in C6 glioma cells by releasing hexokinase from mitochondria.
Topics: Animals; Bucladesine; Cell Communication; Cell Proliferation; Gap Junctions; Glioma; Glucose; Glucos | 2005 |
Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up-regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation.
Topics: Animals; Cell Proliferation; Connexin 43; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Ki | 2006 |
Proliferation of C6 glioma cells is blunted by the increase in gap junction communication caused by tolbutamide.
Topics: Animals; Cell Communication; Cell Division; Cell Membrane Permeability; Connexin 43; Cyclic AMP; Gap | 2001 |